Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

(“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today ...

T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex transmits ...

CD3e molecule, epsilon (CD3E), is a single-pass type I membrane glycoprotein found on T cells. It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3 ...

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Tumor tissue from 868 patients in the QUASAR ...

Targeting the T-cell co-receptor cluster of differentiation 3 (CD3) in type 1 diabetes (T1D) mellitus may impede the autoimmune attack initiated by a triggering event, thus slowing or preventing ...